Clinical Evaluation of 5-Methyl-3-Phenyl-4-Isoxazolyl Penicillin in Staphylococcal Infections

Publisher Website
Google Scholar
Abstract
5-METHYL-3-PHENYL-4-ISOXAZOLYL penicillin (MPI penicillin) is a new synthetic penicillin prepared by acylation of 6-aminopenicillanic acid with 5-methyl-3-phenyl-4-isoxazolecarboxylic acid. The claims for this drug include resistance to penicillinase, in vitro efficacy against staphylococci resistant to penicillin G, as well as various other gram-positive bacteria, and acid stability, which permits oral administration.1 2 3 The present report deals with the in vitro antimicrobial activity of MPI penicillin∥ in comparison to penicillin G and methicillin against 98 isolates of staphylococci from clinical sources, and its efficacy in the treatment of 50 patients with staphylococcal infections. This series includes 17 patients who had failed to respond . . .